Association of Antidiabetic Medications Targeting the Glucagon-Like Peptide 1 Pathway and Heart Failure Events in Patients With Diabetes
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Background Glucagon-like peptide-1 (GLP-1) agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors (GLP-1 agents) may be protective in heart failure (HF). We set out to determine whether GLP-1 agent use is associated with HF risk in diabetics. Methods and Results Retrospective cohort study of members of a large health system. We identified >19,000 adult diabetics from January 1, 2000–July 1, 2012. GLP-1 agent users were matched 1:2 to controls using propensity matching based on age, race, gender, coronary disease, HF, diabetes duration, and number of anti-diabetic medications. The association of GLP-1 agents with time to HF hospitalization was tested with multivariable Cox regression. All-cause hospitalization and mortality were secondary endpoints. We identified 1,426 users of GLP-1 agents and 2,798 controls. Both were similar except for angiotensin-converting enzyme inhibitors/angiotensin receptor blocker (ACEi/ARB) use, number of anti-diabetic medications and age. There were 199 hospitalizations, of which 128 were for HF, and 114 deaths. GLP-1 agents were associated with reduced risk of HF hospitalization (adjusted hazard ratio [aHR] 0.51; 95% confidence interval [CI] 0.34–0.77, p=0.002), all-cause hospitalization (aHR 0.54; 95% CI 0.38–0.74, p=0.001), and death (aHR 0.31; 95% CI 0.18–0.53, p=0.001). Conclusions GLP-1 agents may reduce the risk of HF events in diabetics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470 · cited 2×
“Recently completed randomized controlled trials have shown that DPP-4 inhibitors saxagliptin and alogliptin do not have a significant impact on major adverse cardiac events related to atherosclerotic CV disease (14, 15).”
BackgroundResultAlogliptin after acute coronary syndrome in patients with type 2 diabetes
White, W. B., Cannon, C. P., Heller, S. R., Nissen, S. E., Bergenstal, R. M., Bakris, G. L., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305889 · Cited by 2,502 · cited 1×
“Recently completed randomized controlled trials have shown that DPP-4 inhibitors saxagliptin and alogliptin do not have a significant impact on major adverse cardiac events related to atherosclerotic CV disease (14, 15).”
BackgroundRole of diabetes in congestive heart failure: The Framingham study
Kannel, W. B., Hjortland, M., & Castelli, W. P. (1974) · The American Journal of Cardiology · doi:10.1016/0002-9149(74)90089-7 · Cited by 2,090
Writing Group Members, Roger, V. L., Go, A. S., Lloyd-Jones, D. M., Benjamin, E. J., Berry, J. D., Borden, W. B., Bravata, D. M., Dai, S., Ford, E. S., et al. (2012) · Circulation · doi:10.1161/cir.0b013e3182456d46 · Cited by 1,512 · cited 1×
“7 million individuals affected, an incidence of over 500,000 new cases annually (1) and an estimated 5-year mortality rate of 50% (2).”
BackgroundBan, K., Noyan-Ashraf, M. H., Hoefer, J., Bolz, S.-S., Drucker, D. J., & Husain, M. (2008) · Circulation · doi:10.1161/circulationaha.107.739938 · Cited by 1,057 · cited 1×
“Receptor-independent effects have also been described (18).”
Nikolaidis, L. A., Mankad, S., Sokos, G. G., Miske, G., Shah, A., Elahi, D., & Shannon, R. P. (2004) · Circulation · doi:10.1161/01.cir.0000120505.91348.58 · Cited by 901
Sokos, G. G., Nikolaidis, L. A., Mankad, S., Elahi, D., & Shannon, R. P. (2006) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2006.08.211 · Cited by 656
Dries, D. L., Sweitzer, N. K., Drazner, M. H., Stevenson, L. W., & Gersh, B. J. (2001) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(01)01408-5 · Cited by 286 · cited 1×
“Patients with DM are at high risk of developing HF, and among those who suffer from HF, the presence of DM is associated with worse clinical outcomes (6, 7).”
BackgroundThe effect of diabetes on outcomes of patients with advanced heart failure in the BEST trial
Domanski, M., Krause-Steinrauf, H., Deedwania, P., Follmann, D., Ghali, J. K., Gilbert, E., Haffner, S., Katz, R., Lindenfeld, J., Lowes, B. D., et al. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(03)00856-8 · Cited by 215
Cited by
Margulies, K. B., Hernandez, A. F., Redfield, M. M., Givertz, M. M., Oliveira, G. H., Cole, R., Mann, D. L., Whellan, D. J., Kiernan, M. S., Felker, G. M., et al. (2016) · JAMA · doi:10.1001/jama.2016.10260 · Cited by 706
“Hydralazine 51 (33) 47 (32) Long-acting nitrates 60 (39) 53 (36) Aldosterone antagonist 88 (57) 89 (61) Loop diuretic 151 (98) 146 (100) Digoxin 51 (33) 51 (35) Calcium-channel blocker 12 (8) 5 (3) Lipid-lowering agent 110 (71) 110 (75) Antiplatelet agent 114 (74) 102 (70)”
Graaf, C. D., Donnelly, D., Wootten, D., Lau, J., Sexton, P. M., Miller, L. J., Ahn, J.-M., Liao, J., Fletcher, M. M., Yang, D., et al. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011395 · Cited by 403
A multicenter observational study of incretin-based drugs and heart failure
Filion, K. B., Azoulay, L., Platt, R. W., Dahl, M., Dormuth, C. R., Clemens, K. K., Hu, N., Paterson, J. M., Targownik, L., Turin, T. C., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1506115 · Cited by 196
G Protein–Coupled Receptors Targeting Insulin Resistance, Obesity, and Type 2 Diabetes Mellitus
Riddy, D. M., Delerive, P., Summers, R. J., Sexton, P. M., & Langmead, C. J. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014373 · Cited by 108
“Evidence is now emerging that liraglutide (Velez et al., 2015) and semaglutidemay also have beneficial effects with respect to cardiovascular function and mortality (Marso et al., 2016), increasing the potential benefit of this drug class for treatment of T2DMpatients at risk for cardiovascular…”
Pérez-Belmonte, L. M., Sanz-Cánovas, J., García de Lucas, M. D., Ricci, M., Avilés-Bueno, B., Cobos-Palacios, L., Pérez-Velasco, M. A., López-Sampalo, A., Bernal-López, M. R., Jansen-Chaparro, S., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.851035 · Cited by 35
“There were also significant reductions in all-cause hospitalization (46%) and deaths (69%) (28).”
Background
Metadata
- Authors
- Velez, M., Peterson, E. L., Wells, K., Swadia, T., Sabbah, H. N., Williams, L. K., & Lanfear, D. E.
- Venue
- Journal of Cardiac Failure
- Publisher
- Elsevier BV
- Published
- 2015-01
- Volume
- 21
- Issue
- 1
- Pages
- 2-8
- ISSN
- 1071-9164 (ISSN-L)
- OpenAlex
- W2064262728
- Cited by
- 39
- References
- 9
- FWCI
- 4.31
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.